Introduction
Despite regulatory constraints, methadone has proven uniquely effective as a treatment for opiate dependence. ' 14 Illicit opiate use during methadone treatment should be dose dependent, with higher doses of methadone providing more effective substitution than lower doses. Yet the trend in the late 1970s and 1980s was toward lower doses. Recognition of needle sharing as a vector for HIV transmission may have stayed this trend, but problems still exist.
The study described here systematically addressed pragmatic issues influencing cost, effectiveness of treatment, and HIV spread. The main independent variables were methadone dose and visit frequency. 
Subjects and Methods

Subjects
Data Analysis
An a priori power analysis indicated that a sample of 26 subjects per cell (total sample = 104) was necessary to detect the expected group differences when setting alpha equal to .01 and one minus beta (power) equal to .80. In anticipation of subjects dropping out before the study phase began, 142 subjects were enrolled. The final sample size entering the 24-week treatment phase was 107.
Data analyses were conducted on the basis of all subjects who began the stabilization period (i.e., "intent to treat" analysis, n= 123) and of those subjects who began the 24-week treatment phase when the differences in visit frequency were initiated (n = 107). The stabilization period ensured an adequate sample of those who tolerated the assigned medication dose notwithstanding the exclusion of emergent dual-diagnosis patients. Baseline differences between those who entered the study and those who dropped out during stabilization were evaluated to assess randomization bias.
Subjects were required to complete 75% of the data collection requirements each month to preclude discharge. In practice, no subjects were directly discharged because of intermittent data collection; rather, this percentage served as a definitive end point for subjects who were dropouts. Triplicate data check procedures were used. SAS, BMDP, and SPSS software were used to compute statistical analyses. Group differences in retention were analyzed as survival data (completers were coded as rightcensored) with the use of the SAS module, LIFREG, which allows for discrete and continuous predictor variables. The proportion of urine screens that tested positive for opiates was calculated for weeks 1 to 4, 5 to 8, 9 to 12, 13 to 16, 17 to 20, and 21 to 24, and were analyzed with the use of a maximum likelihood approach to repeated measures analysis of covariance for "unbalanced" data'6"17 ( 
Discussion
This study's design paralleled that of a large clinical trial of cocaine dependency treatment that examined visit frequency and medication dose.7 Parallel designs permit generalization where common findings emerge. The results here, combined with those of the earlier report, are pivotal on the question of visit frequency. The dose-effect data are also clear. Discussion of these two main points, collateral data, and recommendations follow.
That two large clinical trials with patients dependent on different drugs produced parallel results with respect to visit frequency firmly substantiates the generalizability of the findings. Regulations and therapeutic lore requiring that patients receiving methadone attend a clinic 7 days per week during the first 90 days can be viewed as having little benefit and potential hann, and as wasting limited treatment funds. The strength of the effect is further evidenced by a reduced dropout rate at the lower visit requirement despite the 50-mg dose. Further, the twice-weekly urine screens produced no evidence that patients attending the clinic for 2 rather than 5 days each week were more likely to use other drugs.
Decisions regarding methadone dose for this study were affected by the conservative tendency in the clinical science community. The National Institute on Drug Abuse peer-reviewed proposal specified comparison of 50 and 100 mg of methadone. However, pre-study discussion resulted in strong recommendations by consultants that the high dose be 80 mg. The data presented here strongly support the case of greater benefit from higher methadone doses.
Comments on dosing are warranted. First, while higher rather than lower doses are recommended, flexible rather than fixed dosing is reasonable. On the basis of this and other work, we now administer methadone at 1.1 mg/kg. Typically, upward adjustment is needed at lower weights and downward adjustment is needed at higher weights. Doses over 100 mg require informing regulatory agencies. However, agency personnel are responsive to requests from clinics with systematic protocols. Therefore, this regulatory issue is not a deterrent to higher dose administration. parameters for other forms of drug abuse. The data strongly point to the need for policymakers and agencies to substantially revise regulations that (1) limit access to methadone, (2) encourage low-dose regimens, and (3) thus exacerbate the myriad problems associated with opiate dependence, including HIV transmission. This point applies as well to developing regulations for new opiate replacement medication such as buprenorphine. The benefits of these empirically based recommendations will outweigh the risks characterized by the historic concerns of overdose and diversion. Data-based changes in regulations will reduce the burden on the Drug Enforcement Administration, the Food and Drug Administration, and state agencies, and will permit attention to be paid to other aspects of drug control and drug abuse policy. Further, the irony of increased availability of nicotine replacement products along with the current NIDA focus on developing cocaine substitution strategies should persuade the science community, the federal authorities, and the public of the need to reduce impediments in access to opiate substitution treatment. At the same time the expectations of substitution medications are specific: they are to reduce the use of the drug for which they are substituting and thus improve retention. Secondary improvements (e.g., employment) may emerge but depend on the quality of collateral behavior therapy and other factors. 
